NKGen Biotech is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies to treat neurodegenerative and oncological diseases utilizing the proprietary SNK (super-activated) platform. Team of Senior Leadership, Senior Advisors and Management bring together a wealth of knowledge and expertise in neurodegeneration and immune-oncology and are passionate and excited to strengthen the immune system.

The mission of NKGen Biotech is to improve patients' lives in a safe and natural way through innovative cell therapy products and to ultimately become the global leader in immune cell therapeutics.